Platelet inhibitors and hydroxyethyl starch: safe and cost-effective interventions in coronary artery surgeryHICKS, G. L. JR; JENSEN, L. A; NORSEN, L. H et al.The Annals of thoracic surgery. 1985, Vol 39, Num 5, pp 422-425, issn 0003-4975Article

Plaquettes et prostaglandines: perspectives pharmacologiques = Platelets and prostaglandins: pharmacological perspectivesLECOMPTE, T; SAMAMA, M; DRAY, F et al.Gazette médicale de France (1969). 1984, Vol 91, Num 19, pp 84-86, issn 0016-5557Article

Effect of aspirin and dipyridamole on the patency of lower extremity bypass graftsKOHLER, T. R; KAUFMAN, J. L; SALZMAN, E. W et al.Surgery. 1984, Vol 96, Num 3, pp 462-466, issn 0039-6060Article

Why have studies of tailored anti-platelet therapy failed so far?SILLER-MATULA, Jolanta M; JILMA, Bernd.Thrombosis and haemostasis. 2013, Vol 110, Num 4, pp 628-631, issn 0340-6245, 4 p.Article

Bon usage des agents antiplaquettairesMT. Médecine thérapeutique. 2012, Vol 18, Num 4, pp 270-277, issn 1264-6520, 8 p.Article

Antiplatelet therapy in the perioperative periodENGELEN, S; SINNAEVE, P; VAN DAMME, H et al.Acta anaesthesiologica belgica. 2010, Vol 61, Num 3, pp 139-143, issn 0001-5164, 5 p.Conference Paper

Pharmacologie des médicaments antiagrégants = Pharmacology of antiplatelet drugsDE GAETANO, G; CERLETTI, C.Entretiens du Carla (Les). 1985, Vol 4, pp 45-55Article

Using microbial reduction to synthesize carbacyclinZHUO-FENG XIE; FUNAKOSHI, K; SUEMUNE, H et al.Chemical and pharmaceutical bulletin. 1986, Vol 34, Num 7, pp 3058-3060, issn 0009-2363Article

Dyspnoea after antiplatelet agents : the AZD6140 controversySEREBRUANY, V. L; STEBBING, J; ATAR, D et al.International journal of clinical practice (Esher). 2007, Vol 61, Num 3, pp 529-533, issn 1368-5031, 5 p.Article

Evidence that KF4939, a new anti-platelet agent, inhibits phospholipase activation in rabbit platelets: different aspects from cyclic AMP increasing agents and calmodulin antagonistYAMADA, K; SHUTO, K; KUBO, K et al.Archives internationales de pharmacodynamie et de thérapie. 1984, Vol 268, Num 1, pp 141-154, issn 0003-9780Article

New antiplatelet agentsSAMAMA, M.Acta anaesthesiologica belgica. 2010, Vol 61, Num 3, issn 0001-5164, p. 127Conference Paper

Antiplatelet agents: Current drugs and future trendsMESSMORE, Harry L; JESKE, Walter P; WEHRMACHER, William et al.Hematology/oncology clinics of North America. 2005, Vol 19, Num 1, issn 0889-8588, vi, 87-117 [22 p.]Article

Antithrombic drugsFLEMING, J. S; BUYNISKI, J. P; BRUNO, J. J et al.New drugs annual: cardiovascular drugs. 1983, Vol 1, pp 277-316Article

2.113.861 (B) (7139768). - 5NOVEMBRE 1971. IMIDAZOLES ANTI-INFLAMMATOIRESsdPatent

Time-dependent inhibition of platelet aggregation by dopamine and 3-methoxytyramine: important roles of their metabolitesKODAIRA, H; ISHIKAWA, M; KOMODA, Y et al.Biochemical pharmacology. 1984, Vol 33, Num 3, pp 435-441, issn 0006-2952Article

PLATELET AGGREGATION INHIBITORS. 4.N⁶ SUBSTITUTED ADENOSINES1973; J. MEDICIN. CHEM.; U.S.A.; DA. 1973; VOL. 16; NO 4; PP. 358-364; BIBL. 34REF.Serial Issue

Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative PeriodHALL, Richard; MAZER, C. David.Anesthesia and analgesia. 2011, Vol 112, Num 2, pp 292-318, issn 0003-2999, 27 p.Article

Place des antiagrégants plaquettaires en cardiologieZAHRAOUI, Maria; ZOUIR, Imane; TAHIRI, A et al.Espérance médicale. 2005, Vol 12, Num 118, pp 375-378, 4 p.Article

Ticlopidine and platelet function ― rejoinderBERGLUND, U; WALLENTIN, L.Thrombosis and haemostasis. 1986, Vol 55, Num 3, issn 0340-6245, 438Article

Benzofurylaminoalkanones et benzothiénylaminoalkanones à activité antithrombotique potentielle : synthèse et étude de l'inhibition de l'agrégation plaquettaire et du facteur XIII de la coagulation = Benzofurylaminoalkanone and benzothienylaminoalkanone with potential antithrombosis effect: Synthesis and study of platelet aggregation inhibition and factor XIII of the coagulationMAAMER, Mohamed.1984, 185 fThesis

Anticoagulants, thrombolytiques, antiagrégants en réanimation médico-chirurgicale. II. Anticoagulants et thrombolytiques/XIème Session des journées de réanimation médico-chirurgicale, Nancy, 23-25 mars, 1983 = Anticoagulants, fibrinolytics, antiplatelet agents in medecine and surgery intensive care. II. Anticoagulants and fibrinolytics/XIth Session of medecine and surgery intensive care days, Nancy, 23-25 march, 1983Agressologie (Paris). 1983, Vol 24, Num 11, pp 535-590, issn 0002-1148, 49 p.Conference Proceedings

Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueWALLENTIN, Lars; HIMMELMANN, Anders; STOREY, Robert F et al.Thrombosis and haemostasis. 2014, Vol 112, Num 1, pp 12-14, issn 0340-6245, 3 p.Article

Antiplatelet actions of 2-{4-[1-(2-chlorophenyl) piperazinyl]} methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compoundYU-AN DING; TZ-CHONG CHOU; JI-WANG CHERN et al.Thrombosis research. 1995, Vol 77, Num 3, pp 291-303, issn 0049-3848Article

Antiagrégants plaquettaires: choix thérapeutique = Antiplatelet agents: therapeutic choiceMORIAU, M.Louvain médical. 1993, Vol 112, Num 4, pp 313-321, issn 0024-6956Conference Paper

Rationale for the development of antithrombotic, antimetastatic and fibrinolytic durgs: a mechanic point of view, international workshop, Montebello PQ, Canada, April 28-May 1, 1987BASTIDA, E. Ed; BUCHANAN, M. R; OFOSU, F. A et al.Seminars in thrombosis and hemostasis. 1988, Vol 14, Num 1, pp 1-132, issn 0094-6176Conference Proceedings